Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)

NCT00484211 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: NGR-hTNF

Sponsor

AGC Biologics S.p.A.